312 related articles for article (PubMed ID: 12766097)
1. The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial.
Marston WA; Hanft J; Norwood P; Pollak R;
Diabetes Care; 2003 Jun; 26(6):1701-5. PubMed ID: 12766097
[TBL] [Abstract][Full Text] [Related]
2. Use of dermagraft, a cultured human dermis, to treat diabetic foot ulcers.
Gentzkow GD; Iwasaki SD; Hershon KS; Mengel M; Prendergast JJ; Ricotta JJ; Steed DP; Lipkin S
Diabetes Care; 1996 Apr; 19(4):350-4. PubMed ID: 8729158
[TBL] [Abstract][Full Text] [Related]
3. Healing of chronic foot ulcers in diabetic patients treated with a human fibroblast-derived dermis.
Hanft JR; Surprenant MS
J Foot Ankle Surg; 2002; 41(5):291-9. PubMed ID: 12400712
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness modeling of Dermagraft for the treatment of diabetic foot ulcers in the french context.
Allenet B; Parée F; Lebrun T; Carr L; Posnett J; Martini J; Yvon C
Diabetes Metab; 2000 Apr; 26(2):125-32. PubMed ID: 10804327
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of tissue engineering products for the management of neuropathic diabetic foot ulcers: an interim analysis.
Frykberg RG; Cazzell SM; Arroyo-Rivera J; Tallis A; Reyzelman AM; Saba F; Warren L; Stouch BC; Gilbert TW
J Wound Care; 2016 Jul; 25(Sup7):S18-S25. PubMed ID: 29027848
[TBL] [Abstract][Full Text] [Related]
6. Human fibroblast-derived dermal substitute: results from a treatment investigational device exemption (TIDE) study in diabetic foot ulcers.
Warriner RA; Cardinal M;
Adv Skin Wound Care; 2011 Jul; 24(7):306-11. PubMed ID: 21685733
[TBL] [Abstract][Full Text] [Related]
7. A multicenter, randomized, single-blind trial comparing the efficacy of viable cryopreserved placental membrane to human fibroblast-derived dermal substitute for the treatment of chronic diabetic foot ulcers.
Ananian CE; Dhillon YS; Van Gils CC; Lindsey DC; Otto RJ; Dove CR; Pierce JT; Saunders MC
Wound Repair Regen; 2018 May; 26(3):274-283. PubMed ID: 30098272
[TBL] [Abstract][Full Text] [Related]
8. Bilayered bioengineered skin substitute (Apligraf): a review of its use in the treatment of venous leg ulcers and diabetic foot ulcers.
Curran MP; Plosker GL
BioDrugs; 2002; 16(6):439-55. PubMed ID: 12463767
[TBL] [Abstract][Full Text] [Related]
9. A randomized clinical trial of a human acellular dermal matrix demonstrated superior healing rates for chronic diabetic foot ulcers over conventional care and an active acellular dermal matrix comparator.
Cazzell S; Vayser D; Pham H; Walters J; Reyzelman A; Samsell B; Dorsch K; Moore M
Wound Repair Regen; 2017 May; 25(3):483-497. PubMed ID: 28544150
[TBL] [Abstract][Full Text] [Related]
10. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial.
Veves A; Falanga V; Armstrong DG; Sabolinski ML;
Diabetes Care; 2001 Feb; 24(2):290-5. PubMed ID: 11213881
[TBL] [Abstract][Full Text] [Related]
11. Treatment of venous leg ulcers with Dermagraft.
Omar AA; Mavor AI; Jones AM; Homer-Vanniasinkam S
Eur J Vasc Endovasc Surg; 2004 Jun; 27(6):666-72. PubMed ID: 15121121
[TBL] [Abstract][Full Text] [Related]
12. High bacterial load in asymptomatic diabetic patients with neurotrophic ulcers retards wound healing after application of Dermagraft.
Browne AC; Vearncombe M; Sibbald RG
Ostomy Wound Manage; 2001 Oct; 47(10):44-9. PubMed ID: 11890078
[TBL] [Abstract][Full Text] [Related]
13. A prospective, multicentre, randomised controlled study of human fibroblast-derived dermal substitute (Dermagraft) in patients with venous leg ulcers.
Harding K; Sumner M; Cardinal M
Int Wound J; 2013 Apr; 10(2):132-7. PubMed ID: 23506344
[TBL] [Abstract][Full Text] [Related]
14. A Prospective, Randomized, Blinded, Controlled Trial Comparing Transdermal Continuous Oxygen Delivery to Moist Wound Therapy for the Treatment of Diabetic Foot Ulcers.
Driver VR; Reyzelman A; Kawalec J; French M
Ostomy Wound Manage; 2017 Apr; 63(4):12-28. PubMed ID: 28448266
[TBL] [Abstract][Full Text] [Related]
15. A retrospective clinical study of 188 consecutive patients to examine the effectiveness of a biologically active cryopreserved human skin allograft (TheraSkin®) on the treatment of diabetic foot ulcers and venous leg ulcers.
Landsman AS; Cook J; Cook E; Landsman AR; Garrett P; Yoon J; Kirkwood A; Desman E
Foot Ankle Spec; 2011 Feb; 4(1):29-41. PubMed ID: 21135263
[TBL] [Abstract][Full Text] [Related]
16. A metabolically active human dermal replacement for the treatment of diabetic foot ulcers.
Naughton G; Mansbridge J; Gentzkow G
Artif Organs; 1997 Nov; 21(11):1203-10. PubMed ID: 9384327
[TBL] [Abstract][Full Text] [Related]
17. Comparison of negative pressure wound therapy using vacuum-assisted closure with advanced moist wound therapy in the treatment of diabetic foot ulcers: a multicenter randomized controlled trial.
Blume PA; Walters J; Payne W; Ayala J; Lantis J
Diabetes Care; 2008 Apr; 31(4):631-6. PubMed ID: 18162494
[TBL] [Abstract][Full Text] [Related]
18. Cellular versus acellular matrix devices in the treatment of diabetic foot ulcers: Interim results of a comparative efficacy randomized controlled trial.
Tchanque-Fossuo CN; Dahle SE; Lev-Tov H; West KIM; Li CS; Rocke DM; Isseroff RR
J Tissue Eng Regen Med; 2019 Aug; 13(8):1430-1437. PubMed ID: 31070860
[TBL] [Abstract][Full Text] [Related]
19. A prospective, multicenter, randomized, controlled clinical trial comparing a bioengineered skin substitute to a human skin allograft.
Sanders L; Landsman AS; Landsman A; Keller N; Cook J; Cook E; Hopson M
Ostomy Wound Manage; 2014 Sep; 60(9):26-38. PubMed ID: 25211605
[TBL] [Abstract][Full Text] [Related]
20. Dermagraft, a bioengineered human dermal equivalent for the treatment of chronic nonhealing diabetic foot ulcer.
Marston WA
Expert Rev Med Devices; 2004 Sep; 1(1):21-31. PubMed ID: 16293007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
